Gefitinib Price in India: — Brand, Generic and Monthly Cost

Yes. A CDSCO-approved generic contains the same active ingredient at the same dose as Iressa. CDSCO requires bioequivalence data before approving a generic, which means the body absorbs and uses the drug in the same way as the originator tablet. There is no clinical basis for expecting a different outcome from a CDSCO-approved product. If you notice any change after switching — in how you feel or in any side effects — tell your oncology team promptly.

Generally yes, but raise it with your oncologist before making any change. Switching between CDSCO-approved formulations of the same drug at the same dose is a straightforward substitution. Tell your treating team which product you are taking at every review. Any change in how you feel is easier to interpret when your team knows exactly what you have been taking and when you switched.

It depends on your state, your eligibility, and the hospital where you are treated. PMJAY covers cancer as a condition, and some states have separate cancer top-up schemes that list specific targeted medicines. Coverage of oral drugs like gefitinib varies by state scheme. The fastest way to find out is to ask the PMJAY desk at your hospital before your first prescription is filled — bring your health card, your oncologist's prescription and your diagnostic reports.

Jan Aushadhi stores dispense generics at government-fixed prices that are substantially lower than retail rates. The price is set centrally and revised periodically, so the figure at the counter may differ from what you find quoted online. The price is displayed at the store. Not every Jan Aushadhi outlet stocks every medicine, so call ahead. If the store does not have it in stock, ask whether they can place an order.

Hospital pharmacies price medicines based on their procurement contracts and overheads, which do not always produce the lowest price per unit. It is reasonable to compare the hospital pharmacy, a local retail pharmacy and a Jan Aushadhi store for the same CDSCO-approved product. Fill your prescription wherever costs you less. Keep your oncology team informed of which brand or manufacturer you are using, as they may ask this at your next review.

Two pathways are worth checking. First, AstraZeneca operates a patient access programme for Iressa in India for patients who cannot afford the branded price — eligibility is assessed by your oncologist, and the referral is made through them. Second, some state governments supply gefitinib free of charge through government cancer hospitals under NHM procurement; availability varies by state. A hospital social worker or your oncology team's billing office is the best starting point to find out what applies in your situation.